Chen L M, Leuchter R S, Lagasse L D, Karlan B Y
Division of Gynecologic Oncology, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA.
Gynecol Oncol. 2000 Jun;77(3):362-8. doi: 10.1006/gyno.2000.5800.
The aim of this study was to evaluate the role of splenectomy, as a surrogate marker for aggressive tumor cytoreduction in ovarian cancer, and its impact on patient morbidity and survival.
A retrospective cohort study of 35 patients who underwent splenectomy for ovarian cancer cytoreduction between August 1986 and May 1998 was performed. Data abstracted from the medical record included patient demographics, preoperative imaging, surgical procedures, tumor distribution, postoperative complications, chemotherapy treatment, and follow-up information.
Splenectomy was performed in 13 patients at the time of primary cytoreduction and in 22 patients at the time of secondary cytoreduction. Preoperative diagnosis of splenic involvement was frequently made prior to secondary surgery, 77.3% compared to 15.4% of primary cases. In addition, parenchymal splenic involvement was more commonly observed at recurrence, 59.1% vs 23.1% at initial presentation. Disease distribution in secondary cytoreduction cases tended to be more focal, macronodular, and have no ascites. Cytoreduction to less than 1 cm disease was achieved in 100% of primary patients and 86% of secondary patients. Major morbidity (pneumonia, PE, sepsis, pancreatitis, MI) occurred in 23.1% of primary patients and 28.6% of secondary patients. Combining splenectomy with other cytoreductive procedures may make splenectomy itself seem more morbid. With a 17-month median follow-up, median progression-free interval was 24 months in primary patients and 14 months in secondary patients. Among secondary patients, median survival time after splenectomy and cytoreduction was 41 months.
Splenectomy at the time of primary and secondary cytoreduction for ovarian cancer can be performed with acceptable morbidity. Secondary cytoreduction patients may be selected preoperatively by their progression-free interval, prior degree of cytoreduction, and macronodular tumor involvement on imaging studies. Identification of splenic involvement allows for appropriate counseling and preoperative preparation.
本研究旨在评估脾切除术作为卵巢癌积极肿瘤细胞减灭术替代指标的作用及其对患者发病率和生存率的影响。
对1986年8月至1998年5月期间因卵巢癌细胞减灭术而接受脾切除术的35例患者进行回顾性队列研究。从病历中提取的数据包括患者人口统计学信息、术前影像学检查、手术过程、肿瘤分布、术后并发症、化疗治疗及随访信息。
13例患者在初次细胞减灭术时进行了脾切除术,22例患者在二次细胞减灭术时进行了脾切除术。二次手术前经常会对脾受累进行术前诊断,二次手术病例中为77.3%,而初次病例中为15.4%。此外,复发时更常观察到脾实质受累,复发时为59.1%,初次就诊时为23.1%。二次细胞减灭术病例中的疾病分布往往更局限、为大结节性且无腹水。100%的初次手术患者和86%的二次手术患者实现了肿瘤细胞减灭至小于1 cm。主要并发症(肺炎、肺栓塞、败血症、胰腺炎、心肌梗死)在初次手术患者中发生率为23.1%,在二次手术患者中发生率为28.6%。将脾切除术与其他细胞减灭术相结合可能会使脾切除术本身看起来更具病态性。中位随访17个月时,初次手术患者的中位无进展生存期为24个月,二次手术患者为14个月。在二次手术患者中,脾切除术后细胞减灭术的中位生存时间为41个月。
卵巢癌初次和二次细胞减灭术时进行脾切除术,其发病率是可接受的。二次细胞减灭术患者可在术前根据其无进展生存期、先前细胞减灭程度以及影像学研究中肿瘤的大结节性受累情况进行选择。识别脾受累情况有助于进行适当的咨询和术前准备。